Literature DB >> 30187461

Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry.

P Gisondi1, L Bianchi2, P Calzavara-Pinton3, A Conti4, A Chiricozzi5, M Fimiani6, M Pellegrino6, A Giunta2, F Prignano7, R Tiberio8, M Venturini3, G Girolomoni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30187461     DOI： 10.1111/bjd.17133

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  2 in total

1.  Switching Among Biosimilars: A Review of Clinical Evidence.

Authors:  Eleonora Allocati; Brian Godman; Marco Gobbi; Silvio Garattini; Rita Banzi
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

Review 2.  Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review.

Authors:  Hans C Ebbers; Burkhard Pieper; Amine Issa; Janet Addison; Ulrich Freudensprung; Mourad F Rezk
Journal:  Rheumatol Ther       Date:  2019-08-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.